Kazia Therapeutics CEO Dr James Garner talks with SmallCaps about what's on the horizon Posted on August 29th, 2022 . Updated on May 9th, 2023 by Paul LangleyKazia Therapeutics (ASX: KZA) CEO James Garner joins Small Caps to discuss the company’s ongoing development of its lead drug paxalisib, which recently generated positive interim data in a phase one clinical trial for treating brain metastases.